Cholecalciferol versus calcitriol to manage secondary hyperparathyroidism in hemodialysis patients


چاپ صفحه
پژوهان
صفحه نخست سامانه
چکیده مقاله
چکیده مقاله
نویسندگان
نویسندگان
دانلود مقاله
دانلود مقاله
علوم پزشکی کرمانشاه
علوم پزشکی کرمانشاه

نویسندگان: حمیدرضا عمرانی , علی دارایی زاده

کلمات کلیدی: Hyperparathyroidism, Hemodialysis, Cholecalciferol, Calcitriol

نشریه: journal of parathyroid disease , 2 , 6 ,

اطلاعات کلی مقاله
hide/show

کد مقاله 11862
عنوان فارسی مقاله
عنوان لاتین مقاله Cholecalciferol versus calcitriol to manage secondary hyperparathyroidism in hemodialysis patients
نوع مقاله مقاله اصیل (پژوهشی، Original)
بالاترین نمایه نامه بین‌المللی علمی پژوهشی
سطح مقاله هیچکدام
IF
عنوان نشریه journal of parathyroid disease
نوع نشریه ایندکس نشده داخلی
شماره نشریه 2
دوره 6
تاریخ انتشار شمسی 1396/10/14
تاریخ انتشار میلادی
آدرس لینک مقاله/ همایش در شبکه اینترنت http://www.jparathyroid.com
DOI 10.15171/jpd.2018.27
آدرس علمی (Affiliation) نویسنده متقاضی Kermanshah University of Medical Sciences, Kermanshah, Iran. 2Department of Internal Medicine

خلاصه مقاله
hide/show

Introduction: Secondary hyperparathyroidism, is a matter of concern in hemodialysis patients that cause renal osteodystrophy eventually. Objectives: The objective of the study was to compare the efficacy of cholecalciferol with calcitriol for treating secondary hyperparathyroidism. Materials and Methods: This study is a randomized, controlled study. Around 80 patients with hyperparathyroidism (PTH >300 ρg/ mL) and 25(OH)D level <20 ng/mL were divided into two groups to receive cholecalciferol 50 000 IU/3 times in one week or calcitriol 0.25 μg/daily for 12 weeks. Additionally calcium carbonate 1000-1500 mg/d/tablets is prescribed for both groups. Reduction of parathyroid hormone (PTH), changes of plasma albumin-corrected calcium and phosphorus and levels of 25(OH)D were analyzed. Results: Around 40 patients were randomized into each group. At baseline, plasma albumin-corrected calcium, phosphorus and intact PTH and 25(OH)D had no difference between groups. At week 12, intact PTH levels in cholecalciferol and calcitriol groups were 242.38 ± 16.38 ρg/mL and 237.84 ± 13.65 ρg/mL in respectively. Patients who achieved target intact PTH of <300 ρg/mL were 90% in the cholecalciferol and 95% in the calcitriol group (P = 0.447). Serum calcium and phosphorus were not significantly different in both groups. Serum calcium; 9.07 ± 0.36 mg/dL versus 9.00 ± 0.38 mg/dL (P = 0.607), phosphorus; 4.81 ± 0.55 mg/dL versus 4.15 ± 0.42 mg/dL (P = 0.126) in cholecalciferol and calcitriol groups respectively. Furthermore, serum 25(OH)D levels significantly rise in cholecalciferol group. Serum 25(OH)D levels were 62.98 ±21.03 ng/mL in cholecalciferol group and 18.95 ± 22.70 ng/mL in calcitriol group (P < 0.05).

نویسندگان
hide/show

نویسنده نفر چندم مقاله نویسنده مسئول
حمیدرضا عمرانیاولخير
علی دارایی زادهدومبلي

لینک دانلود مقاله
hide/show

نام فایل تاریخ درج فایل اندازه فایل دانلود
cholecalciferol.pdf1397/02/07353342دانلود